Alzheimer's Disease | Norton Healthcare

Indication: Alzheimer's Disease

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease

Sub-indication: Alzheimer's Disease

Study Type: Drug Study

Principal Investigator: Greg Cooper, M.D. Ph.D.
Norton Neuroscience Institute

Sponsor: Sponsor: Eli Lilly

Learn more at ClinicalTrials.gov

Email for more information: NNIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.